Tom Price bought Bristol-Myers Squibb Company (NYSE: BMY)
Tom Price (R-GA), a U.S. Representative, has disclosed 1 trade in Bristol-Myers Squibb Company (BMY) since 2016, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Tom Price bought $1,001 - $15,000 of Bristol-Myers Squibb Company (NYSE: BMY) on March 17, 2016. Since that trade, BMY is up +46.01% against the S&P 500 up +321.76%, an outperformance of -275.75%.
Data updated
Tom Price's BMY trades vs the price
BMY is up +46.01% since Tom Price bought on March 17, 2016, versus +321.76% for the S&P 500.
Performance since this trade
All Tom Price BMY trades
Tom Price & BMY trading FAQ
Is it legal for Tom Price to trade Bristol-Myers Squibb Company (BMY) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Bristol-Myers Squibb Company (BMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Tom Price buy BMY?
Tom Price disclosed a purchase of $1,001 - $15,000 of Bristol-Myers Squibb Company (BMY) on March 17, 2016, according to public STOCK Act filings.
How has BMY performed since Tom Price's trade?
Since Tom Price bought BMY on March 17, 2016, the stock is up +46.01%, versus +321.76% for the S&P 500 over the same period, an outperformance of -275.75%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional BMY trades?
Quantellect tracks every disclosed congressional trade in Bristol-Myers Squibb Company (BMY) on the Bristol-Myers Squibb Company congressional trading page, which aggregates filings across all members of Congress.
Tom Price's BMY tradesAll congressional filings for Bristol-Myers Squibb CompanyTom Price's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.